Luisa Puche's most recent trade in Renovaro Biosciences Inc was a trade of 80,000 Option to Purchase Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Renovaro Biosciences Inc | Puche Luisa | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 80,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Puche Luisa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 80,000 | 80,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 75,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Puche Luisa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 75,000 | 75,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 60,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Puche Luisa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 60,000 | 60,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Puche Luisa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 60,000 | 60,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 60,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2022 | 80,000 | 80,000 | - | - | Option to purchase shares of common stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 75,000 | 75,000 | - | - | Option to purchase shares of common stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 16,266 | 16,266 (0%) | 0% | 0 | Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Dec 2021 | 10,000 | 0 (0%) | 0% | 0 | Common Stock | |
| Renovaro Biosciences Inc | Luisa Puche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 60,000 | 60,000 | - | - | Option to purchase shares of common stock |